Does homocysteine contribute to bone disease in hyperparathyroidism?
Am J Surg
; 195(3): 374-7; discussion 377-8, 2008 Mar.
Article
em En
| MEDLINE
| ID: mdl-18222411
ABSTRACT
BACKGROUND:
Osteoporosis is a complication of hyperparathyroidism (HPT). Hyperhomocysteinemia (HHCy) is an independent risk factor for osteoporotic fractures. We hypothesize that HHCy correlates with bone disease in HPT.METHODS:
A prospectively collected database of 250 patients treated for HPT was reviewed. Patients were categorized into 3 groups group I, normal renal function; group 2, mild renal insufficiency; and group 3, secondary HPT with end-stage renal disease on dialysis. Serum homocysteine levels, markers of bone metabolism, and bone density studies were examined.RESULTS:
The prevalence of HHCy in group 1 (208 patients) was 5%, in group 2 (23 patients), 82%, and in group 3 (19 patients), 78%. Mean (+/-SD) preoperative homocysteinemia (HCy) levels in groups 1, 2, and 3 were 9.3 +/- 4.0, 20 +/- 10.2, and 20.6 +/- 12.3 micromol/L, respectively. Elevated serum markers of bone metabolism increased significantly with decreasing renal function.CONCLUSIONS:
Prevalence of HHCy is low in HPT patients with normal renal function. It is significantly greater in those with dialysis-independent and -dependent renal insufficiency. HHCy correlates with other serum markers of bone metabolism in HPT and may be useful for monitoring progression or improvement.
Texto completo:
1
Base de dados:
MEDLINE
Assunto principal:
Osteoporose
/
Osso e Ossos
/
Hiper-Homocisteinemia
/
Homocisteína
/
Hiperparatireoidismo
Tipo de estudo:
Etiology_studies
/
Observational_studies
/
Risk_factors_studies
Limite:
Female
/
Humans
/
Male
/
Middle aged
Idioma:
En
Ano de publicação:
2008
Tipo de documento:
Article